[{"id":"8b1ef189-345f-4d0b-8046-65f241c6c7d3","acronym":"CR-SEQUENCE","url":"https://clinicaltrials.gov/study/NCT03635021","created_at":"2021-01-18T17:51:02.237Z","updated_at":"2024-07-02T16:35:24.963Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","source_id_and_acronym":"NCT03635021 - CR-SEQUENCE","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 419","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 06/28/2025","primary_completion_date":" 06/28/2025","study_txt":" Completion: 06/28/2025","study_completion_date":" 06/28/2025","last_update_posted":"2023-12-28"},{"id":"31f0020c-0510-41ca-b50a-168b2e6ddd86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03087071","created_at":"2021-01-18T15:12:32.712Z","updated_at":"2024-07-02T16:35:25.486Z","phase":"Phase 2","brief_title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","source_id_and_acronym":"NCT03087071","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS • MAP2K1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type","tags":["KRAS • BRAF • NRAS • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Vectibix (panitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-12-21"},{"id":"a7939463-add1-4ee1-b7a9-f0a971710d58","acronym":"FIRE-4","url":"https://clinicaltrials.gov/study/NCT02934529","created_at":"2021-01-18T14:24:36.504Z","updated_at":"2024-07-02T16:35:29.178Z","phase":"Phase 3","brief_title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","source_id_and_acronym":"NCT02934529 - FIRE-4","lead_sponsor":"Ludwig-Maximilians - University of Munich","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 673","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-15"},{"id":"d396b430-2d8f-45d6-aeae-b6b8e8069381","acronym":"AIO-KRK-0116","url":"https://clinicaltrials.gov/study/NCT04034459","created_at":"2021-01-18T19:47:57.027Z","updated_at":"2024-07-02T16:35:29.371Z","phase":"Phase 2","brief_title":"FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC","source_id_and_acronym":"NCT04034459 - AIO-KRK-0116","lead_sponsor":"Ludwig-Maximilians - University of Munich","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 11/25/2016","start_date":" 11/25/2016","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-11-14"},{"id":"06e0fca2-d97f-4fc4-b976-bea6b4611dff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05694936","created_at":"2023-01-23T14:59:44.826Z","updated_at":"2024-07-02T16:35:30.442Z","phase":"Phase 2","brief_title":"Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05694936","lead_sponsor":"Australasian Gastro-Intestinal Trials Group","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Vectibix (panitumumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 01/23/2023","start_date":" 01/23/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-03"},{"id":"fe7d37d6-22f3-4c41-9187-22556cd9ff0c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169347","created_at":"2021-01-18T20:20:29.434Z","updated_at":"2024-07-02T16:35:41.893Z","phase":"Phase 2","brief_title":"FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer","source_id_and_acronym":"NCT04169347","lead_sponsor":"Criterium, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 12/02/2019","start_date":" 12/02/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-07-27"},{"id":"2f454d62-b561-48df-9aa8-c95f396adca9","acronym":"VOLFI","url":"https://clinicaltrials.gov/study/NCT01328171","created_at":"2021-01-18T05:24:48.418Z","updated_at":"2024-07-02T16:35:45.737Z","phase":"Phase 2","brief_title":"FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","source_id_and_acronym":"NCT01328171 - VOLFI","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR","pipe":" | ","alterations":" EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2023-06-14"},{"id":"233d1a7a-82a0-458e-922e-f1c6e41a5507","acronym":"","url":"https://clinicaltrials.gov/study/NCT02301962","created_at":"2021-01-18T10:52:59.527Z","updated_at":"2024-07-02T16:36:52.433Z","phase":"Phase 4","brief_title":"Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02301962","lead_sponsor":"Dr. Reddy's Laboratories Limited","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 58","initiation":"Initiation: 07/28/2015","start_date":" 07/28/2015","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 01/31/2022","study_completion_date":" 01/31/2022","last_update_posted":"2019-12-16"},{"id":"bb9befbe-d504-4088-a29d-3fbc50540911","acronym":"","url":"https://clinicaltrials.gov/study/NCT01668498","created_at":"2021-01-18T07:12:58.663Z","updated_at":"2024-07-02T16:37:32.678Z","phase":"Phase 2","brief_title":"Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer","source_id_and_acronym":"NCT01668498","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2016-04-19"}]